Karyopharm Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
Karyopharm Therapeutics (US): 1 reconciled FDA prescription therapies, $105.2M 2024 CMS Part D & Medicaid spend, and 35 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2035-01-01 |
| 2024 CMS Total Public Spend | $105.2M |
| 2024 Medicare Part D Spend | $98.2M |
| 2024 Medicaid Spend | $7.0M |
| California HCAI SB 17 Filings | 35 WAC filings (max 32.9% 2-yr change) |